Need to realign patient-oriented and commercial and academic research

An essential component of any new governance strategy would be to bring together all the stakeholders, starting from an analysis of existing and ongoing research, produced independently of vested interests. Patient advocacy groups in myeloma spend millions to support research, hoping to promote better care. With public support they should be in a strong position to call for  redefi nition of the research agenda, in the interests of patients. I hope this approach can be further debated in many other areas of clinical research in oncology and beyond.